Copenhagen, Denmark; February 5, 2014 – Genmab A/S (OMX: GEN) announced today that the Arzerra (ofatumumab) net sales during the fourth quarter of 2013 were GBP 18.8 million (approximately DKK 168 million). This figure consists of net sales in the US of GBP 12.3 million and in the rest of the world of GBP 6.5 million. Under the terms of the collaboration with GlaxoSmithKline (GSK), Genmab expects to receive a royalty payment of approximately DKK 34 million.
Help employers find you! Check out all the jobs and post your resume.
